SteelG.Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys.1979; 5: 1145–1150.
2.
NachmanJ., SatherH., LukensS.Cranial radiation (CRT) improves event free survival (EFS) for high risk patients with acute lymphoblastic leukemia (ALL) showing a rapid response (RR) to BFM induction chemotherapy. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1042.
3.
MinarikL., HallE.J.Taxol in combination with acute and low dose rate irradiation. Radiother Oncol.1994; 32: 124–128.
4.
SteelG.G.Cell synchronization unfortunately may not benefit cancer therapy. Radiother Oncol.1994; 32: 95–97.
5.
ChoyH., BrowneM.J.Paclitaxel as a radiation sensitizer in non-small lung cancer. Semin Oncol.1995; 22: 70–74.
6.
Garcia de PalazzoI., AdamsG.P., SundareshanP.Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res.1993; 53: 3217–3220.
7.
AbramsS.I., HandP.H., TsangK.Y.Mutant ras epitopes as targets for cancer vaccines. Semin Oncol.1996; 23: 118–134.
8.
BernhardE.J., KaoG., CoxA.D.The farnesyltransferase inhibitor 227 is a radiosensitizer of cells expressing activated H-ras. Proc Am Assoc Cancer Res.1996; 37: 604. Abstract 4141.
9.
RudoltzM.R., BernhardE.J., KaoG.D.Apoptosis, cell cycle kinetics, and clonogenic survival in a solid tumor model system expressing bcl-2. Proc Am Assoc Cancer Res.1996; 37: 602. Abstract 4126.
10.
ZhenW., LoviscekK., WalterS.Altered access to the radiation-induced apoptotic pathway in TK6 cells does not affect clonogenic survival after irradiation. Proc Am Assoc Cancer Res.1996; 37: 602. Abstact 4127.
